ImmunityBio, Inc. remains a Buy, with Anktiva’s regulatory and global expansion driving the investment thesis. Learn more ...

ImmunityBio Inc. IBRX shares are up Tuesday following the announcement that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer ...

ImmunityBio (IBRX) added ~7% in the premarket on Wednesday after the company announced that the National Comprehensive Cancer Network has updated its treatment guidelines to include an expanded use of ...

Life-saving treatments for children with orphan illnesses often move slowly, if at all, through the federal approval process.

Even though POP can cause symptoms, like feeling a fullness in the vagina, pelvic pain or pressure, or bowel or urinary changes, POP isn’t always bothersome, Dr. Horner says. Just 3% to 6% of women ...

Erda-iDRS delivers erdafitinib into the bladder over three months, enabling localised therapy and reducing systemic exposure.

Over a median follow-up in responders of 18.0 months (range 15-21), the median duration of complete response was 18.0 months ...

Congenital lower urinary tract obstruction, often presenting as fetal megacystis, is defined in the first trimester by a longitudinal bladder diameter greater than 7 mm on ultrasonography. It most ...